Interferon-Alpha Restores the Deficient Expression of the Cytoadhesion Molecule Lymphocyte Function Antigen-3 by Chronic Myelogenous Leukemia Progenitor Cells

Gargi Upadhyaya,* Susan C. Guba,* Sharon A. Sih, Andrew P. Feinberg, Moshe Talpaz, Hagop M. Kantarjian, Albert B. Deisseroth,* and Stephen G. Emerson*

*Departments of Internal Medicine and Pediatrics, and Cell and Molecular Biology Program, University of Michigan, Ann Arbor, Michigan 48109; †Department of Genetics and Howard Hughes Medical Institute, University of Michigan, Ann Arbor, Michigan, 48109; and ‡Department of Hematology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Abstract

Hematopoietic cells from the malignant clone in chronic myelogenous leukemia (CML) maintain and expand a proliferative advantage over normal hematopoietic cells within the bone marrow. This advantage is often ameliorated or reversed in vivo by IFNα. Based upon earlier studies suggesting decreased adhesiveness of CML progenitor cells, we asked whether CML progenitor cells are deficient in their expression of the cytoadhesion molecule lymphocyte function antigen-3 (LFA-3, CD58), which is normally expressed on hematopoietic progenitors. Progenitor cells from untreated CML patients showed greatly reduced or absent LFA-3 expression, whereas progenitors from patients treated with IFNα in vivo or in vitro expressed surface LFA-3 at more normal levels. LFA-3-deficient CML progenitor cells were unable to stimulate normal regulatory proliferative responses in autologous T cells. We hypothesize that IFNα-sensitive LFA-3 deficiency reflects a cell surface cytoadhesion defect which may help explain adhesive abnormalities of CML progenitor cells in vitro and clonal proliferation in vivo.

(J. Clin. Invest. 1991. 88:2131–2136.) Key words: adhesion • clonal expansion • stem cell

Introduction

The (9;22) Philadelphia translocation of chronic myelogenous leukemia (CML) was the first described nonrandom translocation in malignancy, and has now been molecularly identified with the structurally and functionally abnormal chimeric protooncogene bcr-abl (1–5). CML evolves clinically to more advanced stages through the sequential acquisition of additional cytogenetic abnormalities, a pattern which has recently been demonstrated in common solid tumors as well (6–8).

Despite these important advances in our understanding of CML, the process by which the affected malignant clone maintains its proliferative advantage in vivo remains unknown, despite extensive in vitro investigation. When grown in short-term colony forming assays, CML progenitor cells appear to display the same dependence on hematopoietic growth factors as do normal progenitors. In long-term liquid cultures, progenitors arising from the CML clone survive less well than do normal progenitors, and actually disappear over time leaving behind only normal cells (9). Finally, while in vivo IFNα treatment ameliorates or totally reverses the proliferative advantage of the CML clone, with 15–25% of cases experiencing complete cytogenetic remission (10), no in vitro assay to date has identified a selective effect of IFNα on CML versus normal hematopoietic cells.

Several lines of circumstantial evidence suggests that CML progenitor cells are deficient in their expression of cell surface cytoadhesive molecules. First, Gordon et al. found that CML progenitor cells adhered poorly to bone marrow stromal monolayers in vitro, and more recently have suggested that normal progenitor cell stromal adhesion is mediated through a phosphatidylinositol-linked surface receptor (11, 12). Next, the cytochemical hallmark of CML is decreased expression of the PI-linked ectoenzyme leukocyte alkaline phosphatase (13). Finally, lymphocyte function associated antigen three (LFA-3, CD58) whose cell surface expression can be linked through a phosphatidylinositol-linked receptor (14). Taken together, these observations suggest that deficient expression of critical progenitor cell cytoadhesion molecules, including those which include PI-linked isomers such as LFA-3, might contribute to the pathophysiologic clonal expansion of the CML clone in vivo.

We therefore asked whether CML progenitor cells bear cell surface LFA-3 as detectable in a solid phase immunoabsorption assay. Our results demonstrate that CML progenitor cells are deficient in their expression of LFA-3, and suggest that IFNα treatment in vivo and in vitro restores deficient LFA-3 expression. In addition, the data indicate that CML cells indeed fail to stimulate autoimmunoregulatory T cell responses characteristic of normal bone marrow progenitor cells.

Materials

Bone marrow mononuclear cells. Clinical samples used in this study were obtained coincident to routine diagnostic procedures used to evaluate CML patients at the M.D. Anderson Cancer Center, under a protocol approved by the M.D. Anderson Cancer Center Human Subjects Committee. Normal bone marrow was aspirated under local anesthesia from volunteers following informed consent, under a protocol approved by the University of Michigan Institutional Review Board. Mononuclear cells were prepared by centrifugation over Ficoll-Hypaque (Sigma Chemical Co., St. Louis, MO). 1.077. After three washes in
Iscovec's modified Dulbecco's medium (IMDM) supplemented with 2% FCS. Hycolton Laboratories Inc., Logan, UT), adherent cells were removed by overnight incubation at 10^6 cells/ml in IMDM + 30% FCS over 100-mm plastic dishes (Corning Glass Inc., Corning, NY).

Separation of LFA-3/CD58^+ and - cells. Nonadherent bone marrow mononuclear cells were separated into LFA-3/CD58^+ and - fractions by panning (15, 16). Briefly, the cells were suspended in IMDM plus 5% FCS in the presence of mouse anti-human LFA-3 (TS2.9 ascites, generously provided by Drs. Carol Clayberger and Alan Krenskey, Stanford University, Palo Alto, CA) for 1 h at 4°C, washed, resuspended in PBS plus 5% FCS, and incubated at 4°C over 100-mm plastic tissue culture dishes coated with 5 ml rabbit anti-mouse Ig (100 µg/ml; Zymed Labs., Inc., South San Francisco, CA). After 1 h, the plates were gently tipped and nonadherent, LFA-3^- cells removed by aspiration. After once gently rinsing the plates, 5 ml IMDM plus 5% FCS was added and the adherent cells incubated for 30 min at 37°C under 5% CO2. The previously adherent, LFA-3^+ cells were then recovered by aspiration and the use of a rubber policeman. Analogous procedures were followed to isolate and cells for other antigens, using αHLA-DR (300 µg/10^6 cells; Becton Dickinson and Co., Cockeyesville, MD), αHLA-DQ (αLeu-10, 500 µg/10^6 cells; Becton Dickinson), αCD15 (αLeu-M1, 300 µg/10^6 cells; Becton Dickinson), and αCDw41 (4F7, 100 µg/10^6 cells, generously provided by Dr. William Bigbee, Lawrence Livermore Laboratories), αLFA-1a chain/CD11a and αLFA-1b chain/CD18 (1/200 hybridoma supernatant, both generously provided by Drs. Carol Clayberger and Krenskey).

Methylcellulose cultures. Each fraction was cultured in 0.9% methylcellulose supplemented with 10% deionized BSA and 30% FCS in the presence of interleukin 3 (10 ng/ml, generously provided by Dr. Steven Clark, Genetics Institute, Cambridge, MA) and erythropoietin (2 U/ml, Amgen Biologicals, Thousand Oaks, CA), and erythroid (burst forming unit-erythroid-derived), myeloid (granulocyte-macrophage colony forming unit-derived), and multilineage (granulocyte-erythroid-macrophage-megakaryocyte colony forming unit-derived) colonies enumerated on day 17.

Interferon treatment in vitro. Nonadherent CML bone marrow mononuclear cells were incubated at 10^6 cells/ml in IMDM plus 20% FCS supplemented with 0-200 U/ml IFNγ (Schering Corp., Kenilworth, NJ) for 24 h at 37°C under 5% CO2. Aliquots were withdrawn at 0, 4, 12, and 24 h, the cells separated into LFA-3^+ and LFA-3^- fractions by panning, and progenitor cells enumerated by methylcellulose culture in the presence of IL-3 plus Epo. The data are presented as progenitor cells per 10^6 cell before fractionation.

Detection of the bcr-abl rearrangement by polymerase chain reaction (PCR) in individual colonies. Etidium bromide-stained Nusieve agarose (3%/1%) gels of PCR products, obtained from reverse-transcribed mRNA from myeloid colonies plucked from methylcellulose cultures. Methods: Nonadherent bone marrow cells from a CML patient whose untreated progenitor cells were 92% LFA-3^- were incubated with IFNγ, for 24 h, then fractionated into LFA-3^- and LFA-3^+ fractions by panning, and each fraction cultured for 14 d in methylcellulose. 96% of the colonies were detected in the LFA-3^- fraction. 12 well separated LFA-3^- colonies were plucked with a 10 µl glass pipette, each colony was washed in PBS, and RNA was extracted essentially as described (17). Methylcellulose from adjacent portions of the culture plates was plated and processed in parallel, and RNA from the K562 cell line and normal human bone marrow were processed as positive controls as well. cDNA was synthesized with reverse transcriptase using a specific primer present in both normal and rearranged bcr messages. The cDNA was divided in half for assay on both normal abl and bcr abl. First round PCR primers and nested primers for bcr-abl were as described (17), and nested primers for second round normal abl amplification were GCTCCCGCGCCGTCGGTCTGGTGGCGCAA for exon 1a, GACACAAAGAGCAGGACTTGCTGTCGGCCTG for exon 1b, and CTCGAGACCTGAGGCTCAAGTCAAGTGG for 3' abl sequence. The polymerase chain reaction (18, 19) was performed with Taq polymerase by denaturation at 94°C for 1 min and primer extension at 72°C for 2 min, for 35 rounds with no annealing step. In 11/12 samples normal abl as well as bcr-abl could be detected on an ethidium bromide-stained gel. DNA from all 12 colonies was transferred after electrophoresis to Greenscreen and hybridized with end-labelled internal 3' abl oligonucleotide, at 50°C by the method of Church and Gilbert (20), to confirm the identity of the visualized PCR products and to score samples in which the PCR product could not be visualized directly on a gel.

Stimulation of autologous proliferating T cells in response to progenitors (APL). Highly enriched CML or normal bone marrow progenitor cells were prepared by removing contaminating nonprogenitor cells (T cells, B cells, NK cells, myeloid and erythroid precursors) by negative immunoselection on plastic dishes (15, 16), and irradiated with 20 Gy. 10^5 autologous CD5^+ T cells were incubated with 10^3 irradiated progenitor cells for 8 d, the cultures pulsated with ^3HThDr for 16 h, and the cells were harvested. T cell proliferation was measured by the stimulation index, i.e., the ratio of ^3H incorporation into T cells stimulated with progenitor cells, versus ^3H incorporation into unstimulated T cells (21).

Results

CML progenitor cells are deficient in the expression of cell surface LFA-3 (CD58). Bone marrow mononuclear cells from a normal donor, and from a patient with newly diagnosed, untreated CML, were labelled with murine anti-human LFA-3, or anti-human LFA-1 or anti-HLA-DR, and separated by panning into antibody positive and negative cell fractions (15-16). Each fraction was then cultured in methylcellulose, and progenitor cells measured by enumeration of unilineage and multilineage hematopoietic colonies at 17 d. The normal bone marrow progenitor cells were uniformly LFA-3^+, with 86/86 erythroid burst forming units (BFU-E), 12/12 granulocyte-macrophage colony forming units (CFU-GM), and 14/14 multilineage colony forming cells (CFU-GEMM) partitioning into the LFA-3^- fraction. In contrast, > 95% of the progenitor cells from the CML bone marrow sample partitioned into the LFA-3^- fraction (Table I). Similar results were obtained in 10 normal controls, whose progenitor cells were nearly all LFA-3^- in this assay, and in 17 additional patients with untreated stable phase CML, most or all of whose progenitor cells were LFA-3^-.

This underexpression of cell surface LFA-3 appeared not to be

<table>
<thead>
<tr>
<th>Table I. Fractionation of Normal and CML Progenitor Cells Via the Expression of Cell Surface LFA-3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample</td>
</tr>
<tr>
<td>-------------------------</td>
</tr>
<tr>
<td>Normal BM</td>
</tr>
<tr>
<td>LFA-3^-</td>
</tr>
<tr>
<td>Untreated CML</td>
</tr>
<tr>
<td>LFA-3^-</td>
</tr>
</tbody>
</table>

*Nonadherent bone marrow mononuclear cells were separated into LFA-3^- and - fractions by panning. The + and - fractions were cultured in 0.9% methylcellulose, and erythroid (burst forming unit-erythroid-derived), myeloid (granulocyte-macrophage colony forming unit-derived), and multilineage (granulocyte-erythroid-macrophage-megakaryocyte colony forming unit-derived) colonies enumerated on day 17. The data are presented based on 10^5 cells before LFA-3^- fractionation.
caused by the proliferative bone marrow state of these patients per se, as progenitor cells from three patients with nonleukemic, reactive leukocytosis were 100% LFA-3+ (Fig. 1). This disparity between CML and normal progenitor cell surface antigen expression was not found for several other cell surface proteins expressed on bone marrow cells, including LFA-1 and HLA-DR (Table II). Untreated stable phase CML hematopoietic progenitor cells, therefore, are relatively LFA-3 deficient compared with normal nonleukemic progenitor cells.

Progenitor cells from CML patients treated with interferon a express partially or fully normalized LFA-3 in vivo. Since the treatment of CML with IFNα results in amelioration or reversal of the proliferative advantage of the CML clone in vivo (12), we next examined bone marrow samples from CML patients being treated with IFNα. In contrast to the CML patients before treatment, IFNα-treated CML patients displayed partially or completely restored surface LFA-3 expression, with 30-100% of progenitor cells recovered in the LFA-3+ fraction (Fig. 1, final column). Individual CML patients were then studied both before and after treatment with IFNα to determine if progenitor cell surface LFA-3 expression could be amplified over time following treatment. Progenitor cell surface LFA-3 expression was increased in each of three cases studied, to variable extents, after 3-6 mo of therapy (Fig. 2). These data suggested that treatment with IFNα might partially or completely reverse LFA-3 deficiency on the CML progenitor cells.

Interferon a reverses CML progenitor cell LFA-3 deficiency in vitro. These marrow samples from IFNα-treated CML patients, however, might have contained increased and variable percentages of normal, nonleukemic progenitor cells. Therefore, the observed restoration of progenitor cell LFA-3 expression might have been simply due to sampling of large numbers of nonleukemic progenitors that had been selected in vivo over months of IFNα therapy. We therefore asked whether IFNα could reverse deficient LFA-3 expression in vitro, before clonal selection could occur. Progenitor cells from an untreated CML patient were incubated in 200 U/ml IFNα, the peak plasma dose achieved after subcutaneous administration in vivo, for up to 24 h, fractionated into LFA-3+ and LFA-3- cells by panning, and plated in methylcellulose. Whereas before IFNα treatment, 80% of BFU-E, 83% of CFU-GM, and 90% of CFU-GEMM were LFA-3-, after 24 h in vitro IFNα incubation 75% of BFU-E, 68% of CFU-GM, and 80% of CFU-GEMM were LFA-3+ (Fig. 3). Moreover, while the absolute densities of

<table>
<thead>
<tr>
<th>Cell surface antigen (antibody)</th>
<th>CML BM</th>
<th>Normal BM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gpl A</td>
<td>0±9*</td>
<td>0±0</td>
</tr>
<tr>
<td>HLA-DR</td>
<td>88±7</td>
<td>95±4</td>
</tr>
<tr>
<td>HLA-DQ</td>
<td>7±6</td>
<td>4±3</td>
</tr>
<tr>
<td>CD34</td>
<td>96±3</td>
<td>98±2</td>
</tr>
<tr>
<td>CD15</td>
<td>5±5</td>
<td>7±4</td>
</tr>
<tr>
<td>LFA-1α/CD11a</td>
<td>11±6</td>
<td>9±4</td>
</tr>
<tr>
<td>LFA-1β/CD18</td>
<td>6±3</td>
<td>7±3</td>
</tr>
<tr>
<td>LFA-3/CD58</td>
<td>21±7</td>
<td>93±3</td>
</tr>
</tbody>
</table>

* Percentage of total BFU-E + CFU-GM + CFU-GEMM recovered in the adherent fraction after panning as described in Table I, using the primary murine monoclonal antibodies to the specified epitopes. The data presented are means ± SD for analyses from 7 CML and 10 normal bone marrow samples.
LFA-3\(^+\) progenitor cells did fall during this incubation, the concentration of LFA-3\(^+\) progenitors rose, suggesting that increased LFA-3 expression was caused not simply by rapid selective in vitro toxicity to CML progenitors, but by induction of surface LFA-3 expression on previously LFA-3\(^-\) progenitor cells. This LFA-3 inductive effect was seen at IFN\(_\alpha\) concentrations from 50–1,000 U/ml, which encompasses peak and trough levels obtained during in vivo patient treatment with IFN\(_\alpha\) (Fig. 4). Similar results were obtained in six additional untreated CML patients, with progenitor cell LFA-3 expression increased from 0–13\% to 31–96\% (Table III).

Despite these kinetic and quantitative data, we wished to definitively exclude the possibility that IFN\(_\alpha\) treatment in vitro was selecting for the growth of normal over leukemic progenitor cells in the LFA-3\(^+\) fraction. In these studies, hematopoietic colonies were grown in methylcellulose, individual colonies were plated and suspended in PBS, and RNA extracted and split into two aliquots. Reverse transcriptase polymerase chain reaction was used to amplify specific message for abl and bcr-abl from the two aliquots. In this assay, RNA from colonies containing cells bearing the Ph chromosomal translocation would contain both abl and bcr-abl mRNAs, while colonies from normal hematopoietic progenitors would contain only abl but not bcr-abl mRNAs. The results revealed that RNA analysis of individual colonies plated from the LFA-3\(^+\) fraction following in vitro interferon treatment confirmed that each colony expressed the characteristic bcr-abl transcript as well as the normal abl transcript (Fig. 5). Thus the LFA-3\(^+\) progenitor cells arising after IFN\(_\alpha\) treatment in vitro are indeed leukemic, and therefore reversion of deficient LFA-3 expres-

**Table III. Alpha Interferon Induces LFA-3 Expression on CML Progenitor Cells In Vitro**

<table>
<thead>
<tr>
<th>Patient number</th>
<th>Untreated</th>
<th>Post-IFN(_\alpha)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>16</td>
<td>84</td>
</tr>
<tr>
<td>2</td>
<td>0</td>
<td>32</td>
</tr>
<tr>
<td>3</td>
<td>8</td>
<td>96</td>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>61</td>
</tr>
<tr>
<td>5</td>
<td>0</td>
<td>31</td>
</tr>
<tr>
<td>6</td>
<td>0</td>
<td>41</td>
</tr>
<tr>
<td>7</td>
<td>13</td>
<td>67</td>
</tr>
</tbody>
</table>

* Percent (BFU-E + CFU-GM + CFU-GEMM) in the LFA-3\(^+\) fraction, after separation of nonadherent bone marrow mononuclear cells into LFA-3\(^+\) and LFA-3\(^-\) fractions, as in Table I. Each patient's bone marrow was studied immediately and after incubation for 24 h in IMDM plus 20\% FCS in the presence of 200 U/ml IFN\(_\alpha\). Incubation for 24 h in IMDM/FCS without IFN\(_\alpha\) did not increase LFA-3 expression (data not shown in table). Incubation of normal bone marrow progenitor cells (n = 4) in the presence of 50–200 U/ml IFN\(_\alpha\) did not change LFA-3 expression (96±4 pre-IFN\(_\alpha\), 95±7 post-IFN\(_\alpha\)).
Lymphocyte Function Antigen-3 Deficiency in Chronic Myelogenous Leukemia Progenitor Cells

Discussion

These data indicate that CML progenitor cells are deficient in their expression of the cell surface cytoadhesion molecule LFA-3 (CD58). This deficiency appears to be ameliorated in patients treated with interferon α. Moreover, treatment of CML bone marrow with IFNα in vitro reverses the LFA-3 defect over the course of 24 h, indicating that the effects observed on patients treated with IFNα are not simply the result of clonal selection in vivo.

LFA-3 is an extremely widely expressed cell surface protein, whose only known function is as the binding ligand for the T cell surface protein CD2 (22, 23). Its presence is thought to stabilize the interactions between T cells and their cellular targets, including antigen presenting cells and virally infected cells. Deficiency in LFA-3 on EBV-transformed B cell lines have led to the hypothesis that this deficiency prevents the necessary T cell binding required for proper immune surveillance in vivo (14). Since LFA-3 is so widely expressed, clonal LFA-3 deficiency could lead to escape from T cell–mediated detection and regulation of nonimmune cellular proliferation in a variety of tissues.

These observations suggest a direct role for interferonα-reversible LFA-3 deficiency in the pathogenesis of stable phase CML. Cellular requirements for alloengraftment suggest that normal human bone marrow contains in the range of 10⁶ stem cells, and hematopoiesis is maintained by the relatively balanced expression of multiple hematopoietic stem cell clones. If the cycling progenitor daughter cells of active stem cells are recognized and modulated by autoreactive T cells, then LFA-3 deficiency might allow CML progenitor cells to escape autorecognition and autoregulation. This would exacerbate even a slight intrinsic proliferative advantage by the CML clone. In this regard, the failure of highly enriched progenitor cells from patients with CML to stimulate autologous T cells proliferation is quite interesting, inasmuch as these autoreactive T cells locally suppress the differentiation of hematopoietic progenitor cells (21).

In this context it is noteworthy that paroxysmal nocturnal hemoglobinuria (PNH) cells are deficient in cell surface LFA-3 (24). While PNH and CML have disparate clinical manifestations, both share the feature that an abnormal clone gradually becomes overrepresented within the bone marrow. This shared deficiency suggests that LFA-3 deficiency might lead to overexpression of individual hematopoietic cell clones, not to elevated circulating blood cell counts per se. Whether the peripheral manifestation of the disease includes high white blood cell and platelet counts as in CML, or low blood cell counts and unusual hemolytic sensitivity as in PNH would depend on other pathophysiologic causes distinct from clonal expansion.

Deficient LFA-3 expression might be only one of several cytoadhesion deficiencies contributing to pathophysiologic...
clonal expansion in CML. Leukocyte alkaline phosphatase and LFA-3, both deficient in CML cells at different stages of differentiation, are two members of a class of membrane proteins which may be anchored to the cell surface by linkage to membrane lipids through phosphatidyl inositol (25, 26). Other such proteins include the adhesion proteins NCAM and decay accelerating factor (26). The data of Gordon et al. suggest that primitive hematopoietic cells may adhere to marrow stroma via phospholipase C-sensitive adhesion molecules (11, 12). While LFA-3 is expressed on most cells through both PI-linked and PI-independent forms (26, 27), it is possible that quantitatively decreased expression may both account for the results of our in vitro assays and prevent normal T cell binding in vivo. The present data support the concept that CML cells may suboptimally express critical PI-linked stem cell proteins which mediate adhesion to stromal cells. Deficient expression of such proteins might contribute to the poor survival of CML marrow cultures in vitro and to failure to regulate CML clonal growth in hematopoietic niches in vivo. The present data both lend circumstantial support to such a hypothesis and suggest that IFN\textsubscript{γ}-responsive CML cells might provide a suitable experimental system to isolate such critical adhesion molecules.

In summary, these data indicate that bone marrow progenitor cells from patients with CML fail to normally express cell surface LFA-3, and that this deficiency is ameliorated in vivo and in vitro by IFN\textsubscript{γ}. We hypothesize that this defect may contribute to the clonal advantage enjoyed by the CML stem cell progeny in vivo. Similar deficiencies in yet to be isolated stromal cell cytoadhesion proteins by CML progenitors may lead to the direct isolation of these molecules.

Acknowledgments
The technical assistance of Kelly Hardesty, Sebra Ellerson, and Robin Luttrell, and the secretarial assistance of Ms. Marty Davis is greatly appreciated.

Dr. Emerson was supported by a Scholarship Award from the Leukemia Society of America. This research was supported by PO1 CA 49659 as well as grants from the National Institutes of Health, the American Cancer Society (IM-580), the Klieberg Foundation, the Sid Richardson Foundation and the Gilson-Longenbaugh Foundation. We would like to thank Drs. Carol Clayberger and Alan Krensky for the generous gift of the TS2.9 antibody.

References